Addyi Approved Female Viagra

Addyi (flibanserin): On Tuesday, the US Food and Drug Administration granted its approval for a new drug for pre-menopausal women.Addyi flibanserin

The new drug, officially named Addyi (flibanserin), is also known as the pink pill or for women, and promises to boost libido.

In particular, Sprout Pharmaceutical says it has been designed to treat the hypoactive sexual desire (HSDD) disorder.

This condition has been recognized by the medical community around 40 years. Her symptoms include little or no interest in close relationships, and possibly there are no or almost sexual fantasies.

“HSDD is characterized by low sexual desire that causes intense discomfort or difficulty in interpersonal relationships and may be due to a co-existing medical or psychiatric condition, within the relationship, or the of a medicine.”

How does the medicine work?

Unlike male Viagra, which works by increasing its flow Addyi (flibanserin) works on the brain.

The drug is designed to target prefrontal cortex and neurotransmitter levels dopamine and norepinephrine.

At the same time, the drug reduces levels of serotonin, a neurotransmitter that, when present in the brain at high concentrations, is associated with inhibition of sexuality.

But in their latest report on Addyi, experts from the Food and Drug Administration are warning that they may cause side effects.

Οι δοκιμές έχουν δείξει ότι μπορεί να προκαλέσει χαμηλή αρτηριακή πίεση ή ακόμη και απώλεια της συνείδησης. Μπορεί επίσης να προκαλέσει , nausea, dizziness, drowsiness, insomnia and dry mouth. The risk of these symptoms is even greater when the drug is taken in combination with alcohol or other treatments.

iGuRu.gr The Best Technology Site in Greecefgns

every publication, directly to your inbox

Join the 2.100 registrants.

Written by Dimitris

Dimitris hates on Mondays .....

Leave a reply

Your email address is not published. Required fields are mentioned with *

Your message will not be published if:
1. Contains insulting, defamatory, racist, offensive or inappropriate comments.
2. Causes harm to minors.
3. It interferes with the privacy and individual and social rights of other users.
4. Advertises products or services or websites.
5. Contains personal information (address, phone, etc.).